This HTML5 document contains 35 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB06959/identifier/pdb/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06959/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB06959/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06959/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB06959
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n7:DB06959 n13:DB06959
dcterms:title
(1S)-2-(1H-INDOL-3-YL)-1-{[(5-ISOQUINOLIN-6-YLPYRIDIN-3-YL)OXY]METHYL}ETHYLAMINE
adms:identifier
n9:DB06959 n10:99443430 n11:2EA n12:46937039
n3:IUPAC-Name
n4:271B62C5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B62CB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B62CA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B62C7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B62C8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B62C9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B62C3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B62C4-363D-11E5-9242-09173F13E4C5 n4:271B62C1-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B62C2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B62D1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B62D2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B62CC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B62CD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B62CF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B62CE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B62D0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B62D7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B62D9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B62DA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B62D6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B62D5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B62D8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B62C6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B62D3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B62D4-363D-11E5-9242-09173F13E4C5